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Nuffield Council on Bioethics Report: Novel Techniques for the 
prevention of mitochondrial DNA disorders: an ethical review 




From the first reading I liked this report because it does what all good reports should 
do: it takes a complex subject – pronuclear transfer (PNT) and maternal spindle 
transfer (MST) - explains it clearly (chapter 2), considers the ethical pros and cons for 
its use (chapter 4) in a particular context – the prevention of debilitating mitochondrial 
disease (chapter 1) - in a measured way and, finally, comes to a clear conclusion: that, 
subject to the techniques meeting safety and other regulatory requirements, it would 
be ethical for potential parents to make use of them (in conjunction with IVF) to avoid 
passing on mitochondrial disease (p.xvi).  
 
Before arriving at its conclusions the working party considered a number of ethical 
issues including: the implications for identity; risks and safety issues; the impact upon 
social relationships (parentage and the status of mtDNA donors); germline 
modification; and implications for the wider society and future generations. As might 
be expected, given the credentials of the working group members, the discussion of 
these issues is thorough and thoughtful, and although I may not agree with their final 
recommendations, these are backed by reasoned argument. 
  
The Nuffield report also makes a series of observations about the potential regulatory 
and social status of the mtDNA donor and the clinical implementation of these 
technologies. Regarding the latter, it recommends that if these techniques are used in 
clinical settings, then long-term follow-up studies of any children born should be 
carried out. While I agree that we would need a thorough investigation of the 
intergenerational risks posed by the use of these techniques and that one of the only 
ways to do this is to undertake longitudinal research, it must be noted that 
recommendations like this may serve to further blur the boundary which exists 
between research and clinical activities. The broader societal consequences of 
increasing the ambiguity in this already tenuous relationship are not considered in the 
report.  
 
The risks of using these techniques and safety issues are discussed at length in the 
report, specifically in section 4.66ff and indirectly in other sections in chapter 4. 
Arguably, this emphasis on these issues reflects the fact that in endorsing the 
development of PNT and MST for clinical use the Nuffield Council has taken the step 
of supporting the use of germline modification techniques in humans – germline 
therapy – (4.35) for the first time. This is a bold step and one that needs, and receives, 
careful consideration (see 4.28-4.65, in particular).  
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Born free but still connected  
So why would we want to use in vitro mitochondrial transfer techniques if they are so 
risky and ethically contentious? The working party was of the opinion that the 
primary reason for using these technologies is that they would prevent harm and 
suffering by allowing parents to produce a genetically related child who does not have 
a potentially debilitating or life–limiting inherited disorder (4.1). In contrast to many 
genetic disorders, which can be avoided by using preimplantation genetic or prenatal 
diagnosis (PGD and PND), the complex mode of transmission of mitochondrial 
mutations means that the only way that some (i.e homoplasmic) women can currently 
have a child who is mutation-free is to use donor eggs or to adopt. They must forgo 
the possibility of having a genetic relationship with their offspring. The use of PNT 
and MST would allow both parents to maintain a genetic link with their (mutation-
free) child. But this genetic continuity comes at a price, for it is only possible through 
germline gene therapy, the substitution of the mother’s mtDNA. Although the media  
has described children conceived using these methods as “three parent babies2” the 
Report, having considered the relationship between mtDNA donors and the resultant 
offspring, concludes that mtDNA donation would not confer parenthood in either the 
biological or legal sense (5.7). In this way the Report distinguishes mitochondrial 
donation from gamete donation.  
 
However, while it might be easy to dispel the fears that mtDNA donation will disrupt 
parental relationships, I am not convinced that this Report leaves our view of familial 
relationships completely unscathed. Arguably, the report’s ethical endorsement of 
mitochondrial transfer techniques serves to prioritise the genetic relationship with 
one’s children above other types of familial relationship. Women who are at risk of 
having a child affected with mitochondrial disease are not without reproductive 
options. Some are able to use PGD or PND, others can use gamete donation or 
adoption or they can decide not to reproduce. All of these reproductive solutions are 
available today. Some may be less attractive than others, but all of them enable 
women and their partners to parent. However, with the exception of PGD, they do not 
permit couples to have a genetically related child, and this, it would appear, at least as 
far as the Nuffield report is concerned, is the most important thing. On one level, I can 
understand individuals wanting to have a healthy child that carries their genes; on 
another, I wonder how far we as a society are prepared to go to cater to such desires. 
Is this about parenting children or is it about replicating one’s nuclear DNA? What is 
a family? Will the nuclear family of the 21st century be defined by DNA rather than 
social and economic ties?  
PNT and MST: A step forward or a step too far? 
In recommending that it would be ethical to develop PNT and MST as treatment 
options in the eradication of mitochondrial disease, the Nuffield Council has 
sanctioned germline therapy in humans for the first time. We may have only 37 
mitochondrial genes (1.6), which act as “powerhouse[s]” or “batteries” (1.1), and 
there may, indeed, be a “material boundary” (4.65) (although not a Chinese wall) 
between nuclear and mitochondrial DNA, but by replacing mutated mitrochondria in a 
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fertilised egg we will cross the genetic Rubicon. This may not be a slippery slope as 
such (4.65), but it could be a dodgy step, and when you tread on dodgy steps they may 
give way and sometimes things get broken. We cannot predict what may happen if 
these technologies are used in the future. All we can say is that using MST and PNT 
to produce disease-free genetically related children involves known risks for 
individuals (donors and recipients) and unknown risks for the species, and that 
developing this technology for clinical implementation will use many resources. 
Should we use our scarce resources to develop these technologies so that we can make 
genetically related children who are mutation free? Read the arguments outlined in the 
Nuffield Report and make up your own mind.  
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